Who are trastuzumab deruxtecan (T-DXd)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NERATINIB, Herceptin, Herceptin, Ado Trastuzumab Emtansine, placebo matching lapatinib, PTH followed by dose dense AC of FEC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trastuzumab-deruxtecan-t-dxd.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

trastuzumab deruxtecan (T-DXd) — Competitive Intelligence Brief

trastuzumab deruxtecan (T-DXd) (trastuzumab deruxtecan (T-DXd)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER2-targeting antibody-drug conjugate. Area: Oncology.

phase 3 HER2-targeting antibody-drug conjugate HER2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

trastuzumab deruxtecan (T-DXd) (trastuzumab deruxtecan (T-DXd)) — GI Innovation, Inc.. Trastuzumab deruxtecan (T-DXd) is a HER2-targeting antibody-drug conjugate that delivers a DNA crosslinking agent to cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
trastuzumab deruxtecan (T-DXd) TARGET	trastuzumab deruxtecan (T-DXd)	GI Innovation, Inc.	phase 3	HER2-targeting antibody-drug conjugate	HER2
NERATINIB	NERATINIB		marketed		EGFR, HER2, HER4	2017-01-01
Herceptin	Trastuzumab-Qyyp	Roche	marketed	HER2/neu receptor antagonist monoclonal antibody	HER2 (c-erbB2) proto-oncogene transmembrane receptor protein	1998-01-01
Herceptin	trastuzumab	Roche	marketed	Antibody-drug conjugate (ADC)	HER2 receptor, subdomain IV	1998-01-01
Ado Trastuzumab Emtansine	Ado Trastuzumab Emtansine	Medstar Health Research Institute	marketed	Antibody-drug conjugate (ADC)	HER2 (human epidermal growth factor receptor 2)
placebo matching lapatinib	placebo matching lapatinib	GlaxoSmithKline	marketed	HER2/EGFR tyrosine kinase inhibitor	HER2, EGFR
PTH followed by dose dense AC of FEC	PTH followed by dose dense AC of FEC	Agendia	marketed	Combination chemotherapy regimen with monoclonal antibody	HER2 receptor; microtubule; DNA (topoisomerase II)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER2-targeting antibody-drug conjugate class)

GI Innovation, Inc. · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Shanghai Miracogen Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). trastuzumab deruxtecan (T-DXd) — Competitive Intelligence Brief. https://druglandscape.com/ci/trastuzumab-deruxtecan-t-dxd. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab